• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy.

作者信息

Kusano Y, Yokoyama M, Terui Y, Inoue N, Takahashi A, Yamauchi H, Tsuyama N, Nishimura N, Mishima Y, Takeuchi K, Hatake K

机构信息

Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

出版信息

Blood Cancer J. 2017 Sep 29;7(9):e614. doi: 10.1038/bcj.2017.96.

DOI:10.1038/bcj.2017.96
PMID:28960192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5709758/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9862/5709758/f407ce267c39/bcj201796f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9862/5709758/f407ce267c39/bcj201796f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9862/5709758/f407ce267c39/bcj201796f1.jpg

相似文献

1
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy.可溶性白细胞介素-2受体的高预处理水平是接受R-CHOP样治疗的滤泡性淋巴瘤患者的一个有力预后因素。
Blood Cancer J. 2017 Sep 29;7(9):e614. doi: 10.1038/bcj.2017.96.
2
Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma.R-CHOP疗法的相对剂量强度与晚期滤泡性淋巴瘤患者的预后
Hematol Oncol. 2019 Aug;37(3):303-307. doi: 10.1002/hon.2614. Epub 2019 Apr 26.
3
Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.在利妥昔单抗时代，可溶性白细胞介素-2受体水平可预测接受环磷酰胺、多柔比星、长春新碱和泼尼松化疗的滤泡性淋巴瘤患者的生存率。
Leuk Lymphoma. 2014 Jul;55(7):1584-90. doi: 10.3109/10428194.2013.850167. Epub 2014 Feb 4.
4
Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP.对接受R-CHOP治疗的滤泡性淋巴瘤患者应用FLIPI/FLIPI-2的回顾性研究。
J Clin Exp Hematop. 2012;52(1):77-9. doi: 10.3960/jslrt.52.77.
5
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.滤泡性淋巴瘤基于 III 期 CHOP-利妥昔单抗对比 CHOP+131 碘-替西莫单抗的试验的预后因素模型的比较分析。
Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15.
6
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.在CHOP化疗方案中加入利妥昔单抗可提高3级滤泡性淋巴瘤患者的总生存率和无失败生存率。
Ann Oncol. 2008 Mar;19(3):553-9. doi: 10.1093/annonc/mdm511. Epub 2007 Dec 13.
7
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.idelalisib对高危滤泡性淋巴瘤及初始化学免疫治疗后早期复发的患者有效。
Blood. 2017 Jun 1;129(22):3037-3039. doi: 10.1182/blood-2016-12-757740. Epub 2017 Mar 21.
8
Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.来那度胺联合R-CHOP方案（R2-CHOP）治疗高负荷滤泡性淋巴瘤患者：2期研究
Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 6):12; 14-5.
9
Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.滤泡性淋巴瘤患者对R-CHOP方案产生反应后可溶性白细胞介素-2受体水平的预后价值
Hematology. 2017 Oct;22(9):521-526. doi: 10.1080/10245332.2017.1312204. Epub 2017 Apr 17.
10
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松治疗后滤泡性淋巴瘤的早期复发预示患者死亡风险高：一项来自国家淋巴瘤关爱研究的分析
J Clin Oncol. 2015 Aug 10;33(23):2516-22. doi: 10.1200/JCO.2014.59.7534. Epub 2015 Jun 29.

引用本文的文献

1
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.分子生物标志物在预测滤泡性淋巴瘤患者高级别转化和结局中的作用：一项全面的系统性综述。
Int J Mol Sci. 2024 Oct 17;25(20):11179. doi: 10.3390/ijms252011179.
2
A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma.一项关于循环细胞因子（白细胞介素-2受体和肿瘤坏死因子受体2）与B细胞非霍奇金淋巴瘤风险之间关系的研究。
Ann Hematol. 2025 Jan;104(1):665-673. doi: 10.1007/s00277-024-05996-2. Epub 2024 Sep 24.
3

本文引用的文献

1
Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.低绝对外周血CD4+ T细胞计数预示接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者预后不良。
Blood Cancer J. 2017 Apr 21;7(4):e558. doi: 10.1038/bcj.2017.37.
2
Low absolute CD4 T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma.外周血中CD4 T细胞绝对计数低与滤泡性淋巴瘤患者较差的生存率相关。
Tumour Biol. 2016 Sep;37(9):12589-12595. doi: 10.1007/s13277-016-5124-9. Epub 2016 Jul 7.
3
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
The Impact of Tumor Hypoxia Modulation on sIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial.
肿瘤乏氧调控对初诊弥漫性大 B 细胞淋巴瘤（DLBCL）患者化疗后可溶性白细胞介素 2 受体（sIL-2R）水平的影响：一项随机临床试验。
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1315-1324. doi: 10.31557/APJCP.2024.25.4.1315.
4
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.可溶性白细胞介素-2受体的动态变化区分了弥漫性大B细胞淋巴瘤中的分子异质性和微环境改变。
Biomark Res. 2022 Jul 25;10(1):51. doi: 10.1186/s40364-022-00401-4.
5
Correlation Between Thymoma and Soluble Interleukin-2 Receptor Expression in a Patient with Good Syndrome.一位患有“好综合征”患者胸腺瘤与可溶性白细胞介素-2受体表达之间的相关性
Onco Targets Ther. 2021 Oct 12;14:5045-5049. doi: 10.2147/OTT.S326193. eCollection 2021.
6
Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment.成人T细胞白血病-淋巴瘤治疗的生物标志物与临床前模型
Front Microbiol. 2019 Sep 18;10:2109. doi: 10.3389/fmicb.2019.02109. eCollection 2019.
7
Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma.纳入炎症细胞因子的预后列线图预测侵袭性非霍奇金淋巴瘤患者的总生存。
EBioMedicine. 2019 Mar;41:167-174. doi: 10.1016/j.ebiom.2019.02.048. Epub 2019 Mar 1.
苯达莫司汀-利妥昔单抗或 R-CHOP/R-CVP 一线治疗惰性 NHL 或 MCL 的随机试验：BRIGHT 研究。
Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3.
4
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.苯达莫司汀联合利妥昔单抗与 CHOP 联合利妥昔单抗作为惰性和套细胞淋巴瘤患者一线治疗的比较：一项开放标签、多中心、随机、3 期非劣效性临床试验。
Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
5
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.可溶性白细胞介素 2 受体α促进白细胞介素 2 介导的免疫应答，并预测滤泡 B 细胞非霍奇金淋巴瘤患者的生存时间缩短。
Blood. 2011 Sep 8;118(10):2809-20. doi: 10.1182/blood-2011-03-340885. Epub 2011 Jun 30.
6
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
7
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.在环磷酰胺、长春新碱和泼尼松治疗后使用利妥昔单抗维持治疗可延长晚期惰性淋巴瘤的无进展生存期：III期随机ECOG1496研究结果
J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.
8
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.可溶性白细胞介素-2受体在接受利妥昔单抗联合CHOP（RCHOP）治疗的弥漫性大B细胞淋巴瘤患者中保留预后价值。
Ann Oncol. 2009 Mar;20(3):526-33. doi: 10.1093/annonc/mdn677. Epub 2008 Dec 12.
9
Revised response criteria for malignant lymphoma.恶性淋巴瘤修订后的反应标准。
J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
10
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.B细胞非霍奇金淋巴瘤中肿瘤内CD4+CD25+调节性T细胞对浸润性CD4+T细胞的抑制作用
Blood. 2006 May 1;107(9):3639-46. doi: 10.1182/blood-2005-08-3376. Epub 2006 Jan 10.